A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March 2013 issue of Nature by Prof Dimmler, Boon, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Myocardial Infarction: Ars2 (arsenite-resistance protein 2/Serrate RNA effector molecule homolog) improves ageing- and stress-associated decline in cardiac function via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10). By treating aged people, who are susceptible to cardiac diseases, with Ars2 activators, one may prevent ageing-associated decline in cardiac function. Together, this study suggests, for the first time, that pharmacological formulations encompassing “Ars2 activators” may be used to improve cardiac function following myocardial infarction.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed information: How Ars2 increases the expression of PNUTS/PPP1R10
To cite: Boominathan, Molecular therapy for Myocardial Infarction: Ars2 (arsenite-resistance protein 2/Serrate RNA effector molecule homolog) improves ageing- and stress-associated decline in cardiac function via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 5/April/2015, 14.33, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
